Guangdong Shirongzhaoye Adjusts Valuation Amid Strong Profit Growth and Sales Increase

Guangdong Shirongzhaoye Co., Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation. This revision reflects a shift in the company's valuation metrics, which are essential indicators of its market position and financial health. The company reported a P/E ratio of 31, alongside a Price to Book Value of 0.98, suggesting a balanced valuation perspective. Additionally, the EV to EBIT stands at 41.41, while the EV to EBITDA is recorded at 33.33. These figures provide insight into the company's operational efficiency and profitability relative to its enterprise value. In terms of growth, Guangdong Shirongzhaoye has demonstrated notable performance, with a net profit of CNY 20.6 million for the quarter ending March 2026, reflecting a significant growth rate of 238.52%. Furthermore, net sales for the half-year reached CNY 552.88 million, marking an increase of 22.86%. The company also reported a pre-tax profit of CNY 11.78 million, which grew by 178.9%. With a return on equity (ROE) of 3.12% and a PEG ratio of 0.01, the company maintains a fair valuation profile. The dividend yield stands at 0.17%, indicating a commitment to returning value to shareholders. For more insights on the latest evaluation and financial trends, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.